Pinealon Reconstitution Calculator

Pinealon is the tripeptide Glu-Asp-Arg (EDR), developed in the Russian peptide-bioregulator school as a neuroprotective geroprotector; in aged laboratory primates it improved cognitive function and helped restore neuroimmunoendocrine balance (primate). Mechanistically, it enters the cytoplasm, nucleus, and nucleolus and binds DNA sequence-specifically, preferentially at CNG and CAG motifs (in-vitro). In an Alzheimer's mouse model, EDR docked at promoter regions of CASP3, NES, GAP43, APOE, SOD2, PPARA, and PPARG and prevented dendritic-spine loss, matching in-vitro data where EDR at 200 ng/ml restored mushroom spines by 71% under amyloid toxicity (vs +20% for KED). Downstream signaling involves MAPK/ERK, p53, caspase-3, SOD2/GPX1, and serotonin/calmodulin pathways; EDR also dose-dependently suppresses stress-induced reactive oxygen species (ROS) and delays ERK1/2 activation. Memory improvement has been reported in elderly patients (observational).

No. Pinealon has no FDA or EMA approval for any indication, and controlled clinical trials are lacking. Human experience comes from Russian observational cohorts: elderly polymorbid patients, 150 occupational drivers with psychoadaptive disorders, and locomotive crews. Outside these programs it remains an unapproved compound.

The only documented human dosing is 100 mcg oral capsule twice daily for 2 weeks, which improved biological-age and adaptation markers in locomotive workers. Geriatric and occupational programs used course-based combined regimens (Pinealon + Vezugen) [6, 10]. Rodent studies used intraperitoneal injection (KED tripeptide at 400 µg/kg IP in 5xFAD mice). No head-to-head route data exist. Community protocols (community protocol): 100–500 mcg/day, typically subcutaneous or intranasal, sometimes 100–200 mcg oral twice daily; injectable/intranasal routes are preferred for presumed higher bioavailability.

Documented human courses lasted 2 weeks; all published human programs were course-based rather than continuous [6, 10]. No long-term continuous-use safety data exist. Community convention (community protocol): 10–20-day cycles with off periods between cycles.

No human pregnancy data exist. In rats, prenatal Pinealon under experimental hyperhomocysteinemia improved offspring cognition and cerebellar-neuron redox state (animal), but this does not establish human pregnancy safety; avoid use during pregnancy and breastfeeding. In a 32-person elderly cohort, Pinealon/Vezugen improved CNS activity and biological-age markers, but chemiluminescence showed prooxidant activity and blood CD34+ hematopoietic precursor cells fell: a signal of inhibited hemopoiesis. Pinealon is not a direct antioxidant: it can elevate resting intracellular ROS while lowering the dead-cell fraction in stressed neuronal populations. Caution is warranted with hematologic disease or cytopenia. Occupational cohort publications report benefit outcomes without safety flags [10, 11].

In rats, Pinealon improved Morris-maze learning more than Cortexin in both young and old animals. Under hypoxia, Pinealon increased neurogenesis and normalized IL-6/TNF toward reference levels, while Cortexin mainly suppressed programmed cell death but left IL-6 elevated; in another hypoxic aged-rat model, Cortexin showed stronger effects on free radicals and caspase-3. Against the related tripeptide Vezugen (Lys-Glu-Asp), Vezugen produced a more visible geroprotective effect in elderly humans, and combined Pinealon + Vezugen gave the best outcomes in geriatric and occupational cohorts [6, 10].

No published storage data exist. Community practice (community protocol): lyophilized powder at room temperature short-term (cool, dry, dark for long-term storage); reconstituted solutions refrigerated and used within ~28–30 days; intranasal sprays kept refrigerated.